It is therefore thought that restoring levels of NO can counteract endothelial cell dysfunction and subsequent vasoconstriction and thrombosis [18]. The continued use of ACE inhibitors or statins in patients with vascular disease who develop COVID-19 has been shown to confer a survival advantage in some centres, but introducing them as COVID-19-specific anti-thrombotic agents has yet to be studied [19]. Here, ACE is linked to COVID-19.